Linagliptin

It promotes pancreatic insulin secretion by inhibiting the DPP-4 enzyme that degrades the GLP-1 and GIP intestinal hormones involved in the physiological regulation of glucose, which are activated by eating ^{(EMA 2016, Baetta, 2011, Scheen 2011)}. Administered orally once a day.

Since the last update we have not found published data on its excretion in breast milk.

Its pharmacokinetic data ^{(EMA 2016, Scheen 2011)}: high volume of distribution and high percentage of protein binding make it unlikely that significant amounts will pass into breast milk, but low molecular weight, low metabolism and its effective elimination half-life of 12 hours would facilitate its possible passing into breast milk.

Breastfed infants should be monitored clinically and analytically (blood glucose) during maternal treatment with linagliptin. ^{(Berlin 2005)}

Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.

Very low risk of hypoglycemia in monotherapy. Very low frequency of clinically significant side effects. Dosage up to 120 times higher than normal did not produce side effects. ^{(EMA 2016)}

Diet, exercise, and breastfeeding improve blood sugar levels. 

See below the information of these related products:

• Maternal Diabetes mellitus (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
• Saxagliptin (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
• Vildagliptin (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)